Trials / Terminated
TerminatedNCT00888810
Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer
A Phase II Study Evaluating the Association of Topotecan and Lapatinib in Early Recurrent (Less Than 12 Months)Ovarian or Peritoneal Cancer Patients After First Line of Platinum-Based Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Centre Francois Baclesse · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the trial was to evaluate the efficacy of the association of topotecan and lapatinib in patients who failed first line platinum-based chemotherapy within 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TOPOTECAN | IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles) |
| DRUG | LAPATINIB | Daily oral administration during all the study. 1250 mg/day |
Timeline
- Start date
- 2008-03-01
- First posted
- 2009-04-28
- Last updated
- 2009-04-28
Locations
21 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00888810. Inclusion in this directory is not an endorsement.